Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 6/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542955 | 1.00 | NR1H2 (0.37) | NR1H2NR1H3MAPTTACR1MMP13 | |
| SCHEMBL2549021 | 0.87 | HSD11B1 (0.35) | HSD11B1MCHR1 | |
| SCHEMBL2541261 | 0.85 | MAPT (0.34) | NR1H2NR1H3MAPTTACR1MMP13 | |
| SCHEMBL2549214 | 0.85 | MAPT (0.34) | NR1H2NR1H3MAPTTACR1MMP13 | |
| SCHEMBL12241626 | 0.83 | NR1H2 (0.39) | NR1H2NR1H3MAPTTACR1MMP13 | |
| SCHEMBL1743663 | 0.83 | NR1H2 (0.39) | NR1H2NR1H3MAPTTACR1MMP13 | |
| SCHEMBL9922013 | 0.83 | NR1H2 (0.39) | NR1H2NR1H3MAPTTACR1MMP13 | |
| SCHEMBL12706284 | 0.78 | GPR119 (0.35) | NR1H2NR1H3MAPTTACR1MMP13 | |
| SCHEMBL1595353 | 0.78 | GPR119 (0.35) | NR1H2NR1H3MAPTTACR1MMP13 | |
| SCHEMBL1519808 | 0.76 | CETP (0.41) | MAPTTACR1TGFBR1NOD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | NR1H2 895/4885NR1H3 1119/4885MAPT 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.